AC Immune

AC Immune

AC Immune is a clinical-stage biopharmaceutical company emerging as a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases.
More Details

Since AC Immune’s foundation in 2003, our staff has developed pioneering scientific and clinical expertise in the understanding and treatment of neurodegeneration. Our deep knowledge and cutting-edge technology platforms, SupraAntigen® and Morphomer®, are the engines for our diverse pipeline of clinical and preclinical product candidates.

Our experienced management team combines outstanding scientific, clinical, regulatory, financial and corporate development competencies to build on the seminal work of AC Immune’s founders.

The Board of Directors includes leading industry veterans, who oversee and optimise our corporate strategy and execution. We also benefit from working closely with collaboration partners, investors, clinicians and academic researchers.

  • Recent Milestones: Anti-pTau active immunotherapy (ACI-35.030) progressed into Phase 2b development with partner, J&J; completed focused financing in December raising $50 million in gross proceeds
  • Upcoming Milestones: Amyloid plaque data in H1 and H2 2024 for anti-Abeta active immunotherapy (ACI-24.060) after 6- and 12-months of treatment, respectively
  • Products: AC Immune has a broad pipeline of products in development including active immunotherapy candidates for Alzheimer’s disease targeting Abeta (ACI-24.060) and phospho-Tau (ACI-35.030), and for Parkinson’s disease targeting alpha-synuclein (ACI-7104.056), as well as small molecule drugs and imaging agents for neurodegenerative disease
  • Investors: AC Immune is Nasdaq listed (ACIU) and has many long-term institutional investors such as BVF Partners, Redmile Group, Avidity Partners, Blackrock, Platinum, StemPoint Capital, dievini Hopp, Athos, and others
  • Full Company address & contact details:

Gary Waanders, PhD MBA
Head of Investor Relations and Communications
AC Immune SA
EPFL Innovation Park
Building B

https://www.acimmune.com